ALNY
$ALNY
Alnylam Pharmaceuticals, Inc.
Pioneer in RNA interference therapeutics treating rare genetic diseases.
HealthcareSubscribers
0
Tracking this ticker
Next Report
—
Weekly updates
Latest Report
This week's analysis
ALNY: RNAi Growth Meets Clinical Momentum
Alnylam ($ALNY) is showing renewed momentum after positive vutrisiran data and a technical breakout. Strong analyst coverage and solid fundamentals support upside, though valuation and policy risk warrant caution.
Apr 6, 2026